For treatment of: Mexicor nootropics nervous system, brain.Mexicor nootropics
- For the treatment of internal organs: nervous system, brain
- Appointment: stress, neurosis, alcohol withdrawal syndrome, ischemic heart disease, traumatic brain injury, asthenic conditions, encephalopathy, treatment and prevention of cerebral circulation disorders, autonomic (neurocirculatory) dystonia syndrome, anxiety disorders in neurotic and neurosis-like conditions
- Indications for use:
Consequences of acute cerebral circulatory disorders, including after transient ischemic attacks, in the subcompensation phase as preventive courses; mild TBI, consequences of TBI; encephalopathies of various origins (dyscirculatory, dysmetabolic, post-traumatic, mixed); vegetative dystonia syndrome; mild cognitive disorders of atherosclerotic Genesis; anxiety disorders in neurotic and neurosis-like States; treatment of withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders, post-withdrawal disorders; conditions after acute intoxication with antipsychotic drugs; asthenic conditions; prevention of somatic diseases under the influence of extreme factors and loads; exposure to extreme (stressful) factors.
Increased individual sensitivity to the drug; acute renal failure; acute liver failure. Due to insufficient knowledge of the drug's action — children's age, pregnancy, breastfeeding.
Active substance: Ethylmethylhydroxypyridine succinate – 100 mg
Excipients: potato starch – 54.5 mg, povidone (polyvinylpyrrolidone low-molecular medical 12600±2700) – 4 mg, lactose (milk sugar) – 40 mg, magnesium stearate – 0.5 mg, microcrystalline cellulose – 1 mg
- Manufacturer: Miraxpharma